Diffusion Pharmaceuticals

139 articles with Diffusion Pharmaceuticals

• 

  Biopharma Update on the Novel Coronavirus: May 27

  5/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.

• Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program

  5/26/2020

  First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpoints

• Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market

  5/20/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body's ability to deliver oxygen to the areas where it is needed most, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with certain institutional and accredited investors of 11,428,572

• Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases

  5/20/2020

  Planned study features noted principal investigator, regulatory flexibility, and immediate availability of patients

• Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  5/18/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors to purchase, in a registered direct o

• Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

  5/11/2020

  Expands TSC development to include COVID-19 related Acute Respiratory Distress Syndrome as enrollment in Phase 2 on-ambulance stroke trial is delayed

• Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS

  5/5/2020

  Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles Simultaneous patient enrollment planned in both the U.S. and Eastern Europe to speed time to data readout CHARLOTTESVILLE, Va., May 05, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to del

• Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19

  4/27/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the pre-IND submission to the U.S. Food and Drug Administration (

• Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the CoronavirusOvertaxed healthcare systems will delay enrollment in some geographic locations

  3/24/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it expect delays in enrollment in the Company’s ambulance-based PHAST-TSC phase 2 clinical trial in acute stroke due to the coronavirus. 

• CORRECTION -- Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update

  3/18/2020

  In the news release issued on March 17, 2020 by Diffusion Pharmaceuticals Inc. under the same headline, please note that the third statement by the company's chairman and chief executive officer, David Kalergis, has been clarified.

• Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update

  3/17/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today reported financial results for 2019 and provided a business update.

• Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. GainerDr. Gainer to remain on board of directors

  3/12/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced the retirement of Professor John L. Gainer, Ph.D., the company’s chief science officer. 

• Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC

  2/7/2020

  CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has been granted Patent Number EP2540696 B1 from the European Patent Office. This patent relates to pharmaceutical compositions of trans sodium croce

• Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors

  1/10/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces the appointment of Robert Cobuzzi, Jr., Ph.D., 55, to the Company’s board of directors, effective immediately. 

• Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market

  12/13/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously announced registered direct offering, priced at-the-market, with certain institutional investors of 6,266,787 shares of the Company’s common stock, at a purchase price of $0.5585 per share and associated warrant.

• Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

  12/12/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN). (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into definitive securities purchase agreements with certain institutional investors to purchase in a registered direct offering priced at-the-market 6,266,787 shares of the Company’s common stock, at a purchase price of $0.4335 per share, for aggregate gross proceeds of approximately $2.72 million

• CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

  12/12/2019

  In a release issued under the same headline earlier by Diffusion Pharmaceuticals Inc., please note that the pricing and figures in the first paragraph of the release have changed.

• Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients

  12/10/2019

  Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development

• Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

  11/19/2019

  Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit

• Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering

  11/15/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced the closing of its previously announced public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company